Studies conducted on Ruta graveolens indicate that there are safety issues that need addressing priligy medicine Non steroidal SERM, treatment of dyspareunia due to vaginal atrophy in postmenopausal women, estrogen agonist in vaginal epithelium bone uterus, antagonist in breast